80 related articles for article (PubMed ID: 9464355)
21. Tumor necrosis factor alpha production enhancers with a phenylphthalimide skeleton.
Shibata Y; Sasaki K; Hashimoto Y; Iwasaki S
Biochem Biophys Res Commun; 1994 Dec; 205(3):1992-7. PubMed ID: 7811292
[TBL] [Abstract][Full Text] [Related]
22. New aromatic monoesters of alpha-aminoaralkylphosphonic acids as inhibitors of aminopeptidase N/CD13.
Grzywa R; Sokol AM; Sieńczyk M; Radziszewicz M; Kościołek B; Carty MP; Oleksyszyn J
Bioorg Med Chem; 2010 Apr; 18(8):2930-6. PubMed ID: 20347318
[TBL] [Abstract][Full Text] [Related]
23. Tubulin polymerization inhibitors with a fluorinated phthalimide skeleton derived from thalidomide.
Yanagawa T; Noguchi T; Miyachi H; Kobayashi H; Hashimoto Y
Bioorg Med Chem Lett; 2006 Sep; 16(18):4748-51. PubMed ID: 16870433
[TBL] [Abstract][Full Text] [Related]
24. Aminopeptidase N (EC 3.4.11.2) inhibitors (2006 - 2010): a patent review.
Su L; Fang H; Xu W
Expert Opin Ther Pat; 2011 Aug; 21(8):1241-65. PubMed ID: 21619485
[TBL] [Abstract][Full Text] [Related]
25. Design, synthesis and SAR studies of tripeptide analogs with the scaffold 3-phenylpropane-1,2-diamine as aminopeptidase N/CD13 inhibitors.
Shang L; Fang H; Zhu H; Wang X; Wang Q; Mu J; Wang B; Kishioka S; Xu W
Bioorg Med Chem; 2009 Apr; 17(7):2775-84. PubMed ID: 19299146
[TBL] [Abstract][Full Text] [Related]
26. Phenylhomophthalimide-type NOS inhibitors derived from thalidomide.
Noguchi T; Sano H; Shimazawa R; Tanatani A; Miyachi H; Hashimoto Y
Bioorg Med Chem Lett; 2004 Aug; 14(16):4141-5. PubMed ID: 15261258
[TBL] [Abstract][Full Text] [Related]
27. Synthesis of 1,3,4-thiadiazole derivatives as aminopeptidase N inhibitors.
Li SH; Li G; Huang HM; Xiong F; Mai X; Kuang BH; Liu CM; Tu GG
Pharmazie; 2009 Feb; 64(2):67-70. PubMed ID: 19320275
[TBL] [Abstract][Full Text] [Related]
28. Novel aminopeptidase N inhibitors derived from antineoplaston AS2-5 (Part I).
Li X; Wang J; Li J; Wu J; Li Y; Zhu H; Fan R; Xu W
Bioorg Med Chem; 2009 Apr; 17(8):3053-60. PubMed ID: 19329328
[TBL] [Abstract][Full Text] [Related]
29. [Preparation of novel specific aminopeptidase inhibitors with a cyclic imide skeleton].
Takahashi H; Komoda M; Kakuta H; Hashimoto Y
Yakugaku Zasshi; 2000 Oct; 120(10):909-21. PubMed ID: 11082703
[TBL] [Abstract][Full Text] [Related]
30. Identification of very potent inhibitor of human aminopeptidase N (CD13).
Grzywa R; Oleksyszyn J; Salvesen GS; Drag M
Bioorg Med Chem Lett; 2010 Apr; 20(8):2497-9. PubMed ID: 20307982
[TBL] [Abstract][Full Text] [Related]
31. Discovery of a dual-function peptide that combines aminopeptidase N inhibition and kinin B1 receptor antagonism.
Gera L; Fortin JP; Adam A; Stewart JM; Marceau F
J Pharmacol Exp Ther; 2006 Apr; 317(1):300-8. PubMed ID: 16368899
[TBL] [Abstract][Full Text] [Related]
32. Alpha-glucosidase inhibitors with a phthalimide skeleton: structure-activity relationship study.
Takahashi H; Sou S; Yamasaki R; Sodeoka M; Hashimoto Y
Chem Pharm Bull (Tokyo); 2000 Oct; 48(10):1494-9. PubMed ID: 11045457
[TBL] [Abstract][Full Text] [Related]
33. Angiotensin AT4 receptor ligand interaction with cystinyl aminopeptidase and aminopeptidase N: [125I]Angiotensin IV only binds to the cystinyl aminopeptidase apo-enzyme.
Demaegdt H; Lenaerts PJ; Swales J; De Backer JP; Laeremans H; Le MT; Kersemans K; Vogel LK; Michotte Y; Vanderheyden P; Vauquelin G
Eur J Pharmacol; 2006 Sep; 546(1-3):19-27. PubMed ID: 16919623
[TBL] [Abstract][Full Text] [Related]
34. Novel aminopeptidase N inhibitors derived from antineoplaston AS2-5 (Part II).
Li X; Wang Y; Wu J; Li Y; Wang Q; Xu W
Bioorg Med Chem; 2009 Apr; 17(8):3061-71. PubMed ID: 19339187
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of alanyl aminopeptidase induces MAP-kinase p42/ERK2 in the human T cell line KARPAS-299.
Lendeckel U; Kähne T; Arndt M; Frank K; Ansorge S
Biochem Biophys Res Commun; 1998 Nov; 252(1):5-9. PubMed ID: 9813136
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors.
Shinji C; Maeda S; Imai K; Yoshida M; Hashimoto Y; Miyachi H
Bioorg Med Chem; 2006 Nov; 14(22):7625-51. PubMed ID: 16877001
[TBL] [Abstract][Full Text] [Related]
37. Alpha-glucosidase inhibitors with a 4,5,6,7-tetrachlorophthalimide skeleton pendanted with a cycloalkyl or dicarba-closo-dodecaborane group.
Sou S; Takahashi H; Yamasaki R; Kagechika H; Endo Y; Hashimoto Y
Chem Pharm Bull (Tokyo); 2001 Jun; 49(6):791-3. PubMed ID: 11411542
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and evaluation of novel sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors.
Cheng XC; Wang Q; Fang H; Tang W; Xu WF
Bioorg Med Chem; 2008 May; 16(10):5398-404. PubMed ID: 18440232
[TBL] [Abstract][Full Text] [Related]
39. Synthesis of new sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors.
Cheng XC; Wang Q; Fang H; Tang W; Xu WF
Bioorg Med Chem; 2008 Sep; 16(17):7932-8. PubMed ID: 18718763
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and anticonvulsant evaluation of some N-substituted phthalimides.
Wiecek M; Kieć-Kononowicz K
Acta Pol Pharm; 2009; 66(3):249-57. PubMed ID: 19645325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
